Danimer Scientific — FY2022 Earnings Presentation
10 slides from Danimer Scientific's earnings presentation, Mar 28, 2023
Slide 1: Fourth Quarter & Full Year 2022 Earnings Presentation
Fourth Quarter & Full Year 2022 Earnings Presentation March 28, 2023
Slide 2: Disclaimer
Disclaimer This presentation (“Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitatio
Slide 3: Danimer Investment Highlights
Danimer Investment Highlights Kentucky Plant Serves Near-Term Demand 1 2 3 4 5 6 PHA-Based Resins are Superior and Disruptive Sustainability Mandate Drives Permanent Adoption Short, Medium & Long-Term Strategic Finance Initiatives Ongoing Opportunity for Margin Expansion World-Class Teams and a Powe
Slide 4: Kentucky Manufacturing – Process & Capability
Kentucky Manufacturing – Process & Capability¹ Downstream Processing Unique Engineering Expertise Five Independent Vessels Fermentation High-Volume Extrusion Lines Blending, Pelletization & Extrusion Blending & Extrusion Engineered Materials Science Bacterial Production of PHA Proprietary Biotechnol
Slide 5: Recent Customer Highlights
Recent Customer Highlights Launched a new customer making specialty plastic containers for consumable dry-goods Zespri announced, through HAVI, plans for PHA-based cutlery in its snack business PHA-based cutlery launch planned with an additional customer for mid-year. Excited to work closer with HAV
Slide 6: Q4 and Full Year 2022 Financial Summary
Q4 and Full Year 2022 Financial Summary Sales reflects $7.3 mm of growth in PHA-related sales more than offset by $9.9 mm of lower PLA-related sales, including $9.1 mm due to the Ukraine conflict, and service revenues of $4.8 mm compared to $8.0 mm in fiscal 2021 as customers move to commercializati
Slide 7: Financial Outlook
Financial Outlook Adjusted EBITDA Expect 2023E Baseline Capex of $26 million to $31 million, excluding any DoE loan proceeds
Slide 8: danimer ~
te danimer ~ scientific
Slide 9: EBITDA Reconciliation
EBITDA Reconciliation Note: Totals may not foot due to rounding.
Slide 10: Adjusted Gross Profit Reconciliation
Adjusted Gross Profit Reconciliation Note: Totals may not foot due to rounding.